PMID- 35643269
OWN - NLM
STAT- MEDLINE
DCOM- 20220902
LR  - 20220916
IS  - 1549-9642 (Electronic)
IS  - 1549-9634 (Linking)
VI  - 44
DP  - 2022 Aug
TI  - Galactose-modified nanoparticles for delivery of microRNA to mitigate the 
      progress of abdominal aortic aneurysms via regulating macrophage polarization.
PG  - 102564
LID - S1549-9634(22)00050-8 [pii]
LID - 10.1016/j.nano.2022.102564 [doi]
AB  - BACKGROUND: Abdominal aortic aneurysms (AAA) are chronic inflammation in nature 
      and are closely related to macrophages. The purpose was to explore regulating 
      macrophage polarization with target-macrophage nanoparticles impacting the 
      development of AAA. METHODS: Galactose-modified nanoparticles were prepared by 
      self-assembly technology for delivering microRNA (miR)-223. In 
      AngiotensinII-induced experimental AAA model, miR-223-loaded nanoparticles 
      (MirNPs) or PBS was injected at day 7 before and after operation, respectively. 
      Cultured cells and aortic specimen were collected to be analyzed with histology 
      and biochemical examination. RESULTS: In vitro, miR-223 promoted bone 
      marrow-derived macrophages (BMDMs) to polarize to M2. In experimental AAA model, 
      MirNPs significantly decreased the AAA incidence and the ratio of M1 macrophages 
      and production of related proinflammatory cytokines. Furthermore, MirNPs also 
      reduced the expression of the NLRP3 inflammasome. CONCLUSION: Our findings 
      suggested that miR-223-loaded nanoparticles targeting macrophage polarization may 
      mitigate AAA progression via downregulating of NLRP3.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Chen, Xing
AU  - Chen X
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Wu, Yunlong
AU  - Wu Y
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Li, Rui
AU  - Li R
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Li, Chenghao
AU  - Li C
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Xu, Li
AU  - Xu L
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China. Electronic address: 
      unionxuli@hust.edu.cn.
FAU - Qiao, Weihua
AU  - Qiao W
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China. Electronic address: 
      weihua_qiao@hust.edu.cn.
FAU - Dong, Nianguo
AU  - Dong N
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China. Electronic address: 
      dongnianguo@hust.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220526
PL  - United States
TA  - Nanomedicine
JT  - Nanomedicine : nanotechnology, biology, and medicine
JID - 101233142
RN  - 0 (MicroRNAs)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (Nanoparticle Drug Delivery System)
RN  - X2RN3Q8DNE (Galactose)
SB  - IM
MH  - Animals
MH  - *Aortic Aneurysm, Abdominal/drug therapy/genetics
MH  - Disease Models, Animal
MH  - Galactose/chemistry
MH  - *Macrophages/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - *MicroRNAs/genetics/metabolism/pharmacology
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/genetics/metabolism
MH  - *Nanoparticle Drug Delivery System
MH  - *Nanoparticles/chemistry
OTO - NOTNLM
OT  - Abdominal aortic aneurysm
OT  - Macrophage polarization
OT  - NLRP3
OT  - Nanoparticles
OT  - microRNA-223
COIS- Declaration of competing interest The authors declared that they do not have 
      anything to disclose regarding conflict of interest with respect to the 
      manuscript.
EDAT- 2022/06/02 06:00
MHDA- 2022/09/03 06:00
CRDT- 2022/06/01 09:23
PHST- 2022/01/25 00:00 [received]
PHST- 2022/04/28 00:00 [revised]
PHST- 2022/05/03 00:00 [accepted]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/09/03 06:00 [medline]
PHST- 2022/06/01 09:23 [entrez]
AID - S1549-9634(22)00050-8 [pii]
AID - 10.1016/j.nano.2022.102564 [doi]
PST - ppublish
SO  - Nanomedicine. 2022 Aug;44:102564. doi: 10.1016/j.nano.2022.102564. Epub 2022 May 
      26.